Does the media prefer CHRS or ANNX?

In the previous week, Coherus Oncology had 2 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Coherus Oncology and 4 mentions for Annexon. Annexon's average media sentiment score of 0.72 beat Coherus Oncology's score of 0.16 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABUS or CHRS?

In the previous week, Coherus Oncology had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Coherus Oncology and 1 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.16 beat Arbutus Biopharma's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ODTX or CHRS?

Coherus Oncology has higher revenue and earnings than Odyssey Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Odyssey Therapeutics N/A N/A N/A N/A N/A Coherus Oncology $50.94M 3.96 $168.02M -$1.03 N/A

Does the media prefer ODTX or CHRS?

In the previous week, Odyssey Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for Odyssey Therapeutics and 6 mentions for Coherus Oncology. Odyssey Therapeutics' average media sentiment score of 0.38 beat Coherus Oncology's score of 0.16 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CHRS or GERN more profitable?

Geron has a net margin of -34.17% compared to Coherus Oncology's net margin of -259.41%. Geron's return on equity of -24.48% beat Coherus Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Coherus Oncology -259.41% -222.75% -52.11% Geron -34.17% -24.48% -10.30%

Does the media favor CHRS or GERN?

In the previous week, Geron had 20 more articles in the media than Coherus Oncology. MarketBeat recorded 26 mentions for Geron and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.16 beat Geron's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Geron 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CHRS or KURA?

In the previous week, Kura Oncology had 3 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for Kura Oncology and 6 mentions for Coherus Oncology. Kura Oncology's average media sentiment score of 0.71 beat Coherus Oncology's score of 0.16 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coherus Oncology (CHRS) Competitors

$1.30 +0.04 (+2.76%)

As of 02:13 PM Eastern

Compare

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Annexon (ANNX), Arbutus Biopharma (ABUS), Odyssey Therapeutics (ODTX), Geron (GERN), and Kura Oncology (KURA). These companies are all part of the "biotechnology" industry.

How does Coherus Oncology compare to Annexon?

Coherus Oncology (NASDAQ:CHRS) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Coherus Oncology had 2 more articles in the media than Annexon. MarketBeat recorded 6 mentions for Coherus Oncology and 4 mentions for Annexon. Annexon's average media sentiment score of 0.72 beat Coherus Oncology's score of 0.16 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

72.8% of Coherus Oncology shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 10.3% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Coherus Oncology currently has a consensus price target of $8.67, suggesting a potential upside of 564.11%. Annexon has a consensus price target of $15.33, suggesting a potential upside of 190.18%. Given Coherus Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Annexon has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Annexon's return on equity of -101.19% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Annexon	N/A	-101.19%	-75.99%

Coherus Oncology has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.96	$168.02M	-$1.03	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Coherus Oncology beats Annexon on 9 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Arbutus Biopharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Arbutus Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	63.91	-$33.50M	$0.83	5.49
Coherus Oncology	$50.94M	3.96	$168.02M	-$1.03	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Coherus Oncology had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Coherus Oncology and 1 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.16 beat Arbutus Biopharma's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Coherus Oncology's net margin of -259.41%. Arbutus Biopharma's return on equity of 129.32% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential upside of 9.77%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 564.11%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Coherus Oncology beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

72.8% of Coherus Oncology shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Odyssey Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for Odyssey Therapeutics and 6 mentions for Coherus Oncology. Odyssey Therapeutics' average media sentiment score of 0.38 beat Coherus Oncology's score of 0.16 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Odyssey Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 54.78%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 564.11%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Odyssey Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Odyssey Therapeutics' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Coherus Oncology	-259.41%	-222.75%	-52.11%

Coherus Oncology has higher revenue and earnings than Odyssey Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A
Coherus Oncology	$50.94M	3.96	$168.02M	-$1.03	N/A

Summary

Odyssey Therapeutics beats Coherus Oncology on 7 of the 11 factors compared between the two stocks.

How does Coherus Oncology compare to Geron?

Coherus Oncology (NASDAQ:CHRS) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Geron has a net margin of -34.17% compared to Coherus Oncology's net margin of -259.41%. Geron's return on equity of -24.48% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Geron	-34.17%	-24.48%	-10.30%

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Coherus Oncology currently has a consensus price target of $8.67, suggesting a potential upside of 564.11%. Geron has a consensus price target of $4.00, suggesting a potential upside of 171.19%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Coherus Oncology has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.96	$168.02M	-$1.03	N/A
Geron	$204.56M	4.63	-$83.50M	-$0.11	N/A

In the previous week, Geron had 20 more articles in the media than Coherus Oncology. MarketBeat recorded 26 mentions for Geron and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.16 beat Geron's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	5 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Coherus Oncology and Geron tied by winning 8 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Kura Oncology?

Coherus Oncology (NASDAQ:CHRS) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 564.11%. Kura Oncology has a consensus price target of $25.46, indicating a potential upside of 165.64%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Coherus Oncology has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.96	$168.02M	-$1.03	N/A
Kura Oncology	$67.48M	12.61	-$278.67M	-$3.35	N/A

In the previous week, Kura Oncology had 3 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for Kura Oncology and 6 mentions for Coherus Oncology. Kura Oncology's average media sentiment score of 0.71 beat Coherus Oncology's score of 0.16 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has a net margin of -259.41% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Kura Oncology	-411.19%	-141.95%	-43.28%

72.8% of Coherus Oncology shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Coherus Oncology and Kura Oncology tied by winning 8 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$201.62M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.27	9.08	269.95	24.78
Price / Sales	3.96	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.61	17.64	11.25	6.43
Net Income	$168.02M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-9.38%	5.21%	3.49%	2.53%
1 Month Performance	-15.26%	-1.94%	-0.66%	-1.03%
1 Year Performance	59.15%	60.76%	77.20%	23.28%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	2.2457 of 5 stars	$1.31 +2.8%	$8.67 +564.1%	+54.9%	$201.62M	$50.94M	N/A	330	Earnings Report Gap Up
ANNX Annexon	3.6335 of 5 stars	$5.43 +3.3%	$15.33 +182.6%	+129.2%	$887.36M	N/A	N/A	60	Positive News Upcoming Earnings Gap Up
ABUS Arbutus Biopharma	1.0389 of 5 stars	$4.47 +2.6%	$5.00 +11.8%	+36.2%	$879.05M	$14.08M	5.36	90
ODTX Odyssey Therapeutics	3.8408 of 5 stars	$18.19 +0.3%	$32.00 +75.9%	N/A	$873.68M	$1.06M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
GERN Geron	2.2121 of 5 stars	$1.35 +5.1%	$4.00 +197.4%	+15.6%	$862.85M	$196.12M	N/A	70	Earnings Report Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

How does Coherus Oncology compare to Annexon?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Summary

How does Coherus Oncology compare to Odyssey Therapeutics?

Summary

How does Coherus Oncology compare to Geron?

Summary

How does Coherus Oncology compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. ANNX, ABUS, ODTX, GERN, and KURA

How does Coherus Oncology compare to Annexon?

Does the media prefer CHRS or ANNX?

Which has more volatility and risk, CHRS or ANNX?

Do insiders & institutionals hold more shares of CHRS or ANNX?

Do analysts rate CHRS or ANNX?

Is CHRS or ANNX more profitable?

Which has stronger earnings and valuation, CHRS or ANNX?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Which has more risk & volatility, ABUS or CHRS?

Which has better earnings and valuation, ABUS or CHRS?

Do institutionals & insiders hold more shares of ABUS or CHRS?

Does the media prefer ABUS or CHRS?

Is ABUS or CHRS more profitable?

Do analysts prefer ABUS or CHRS?

Summary

How does Coherus Oncology compare to Odyssey Therapeutics?

Do institutionals & insiders have more ownership in ODTX or CHRS?

Does the media prefer ODTX or CHRS?

Do analysts rate ODTX or CHRS?

Is ODTX or CHRS more profitable?

Which has higher earnings & valuation, ODTX or CHRS?

Summary

How does Coherus Oncology compare to Geron?

Is CHRS or GERN more profitable?

Do institutionals & insiders have more ownership in CHRS or GERN?

Which has more volatility & risk, CHRS or GERN?

Do analysts prefer CHRS or GERN?

Which has higher valuation & earnings, CHRS or GERN?

Does the media favor CHRS or GERN?

Summary

How does Coherus Oncology compare to Kura Oncology?

Do analysts prefer CHRS or KURA?

Which has more volatility and risk, CHRS or KURA?

Which has stronger valuation & earnings, CHRS or KURA?

Does the media favor CHRS or KURA?

Is CHRS or KURA more profitable?

Do insiders and institutionals believe in CHRS or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools